Researchers developed modelling methods that captured elements of the interplay of ecological, epidemiological, and socio-economic factors.to predict the risk of Ebola virus disease across time and space.
The US Food and Drug Administration (FDA) has allowed marketing of a rapid diagnostic test (RDT) to detect Ebola virus antigens (proteins) in human blood from certain living individuals and samples from certain recently deceased individuals suspected to have died from Ebola. This is the first rapid diagnostic test the FDA has allowed to be marketed in the US for the Ebola Virus Disease (EVD).
A World Health Organization (WHO) report stated Ebola infections are shifting from densely populated urban areas toward sparsely populated rural areas in the Democratic Republic of Congo. The outbreak just had its 1,000th survivor.
On September 10, 2019, through its regular event-based surveillance process, WHO received unofficial reports regarding the death of a person with suspected Ebola Virus Disease (EVD) case in Dar es Salaam, United Republic of Tanzania. On September 11, 2019, through its regular event-based surveillance process, WHO was made aware of unofficial reports that a RT-PCR test performed at the Tanzanian National Health Laboratory was positive for EVD for this patient.
On 31 March 19 scientists at Canada’s National Microbiology Lab (NML) shipped viable Ebola and Henipah viruses to Beijing on a commercial Air Canada flight.
On August 221, 2019 the World Health Organization (WHO) stated the third case of Ebola was identified in South Kivu province. The individual was a patient who contracted the virus at a health center where other Ebola patients had been treated.
This article acknowledges the importance of recent Ebola therapeutics and vaccine breakthroughs but also highlights the importance of infection control, community engagement, and disease surveillance as deciding factors in combating the Ebola crisis in the Democratic Republic of Congo.
Two treatments for Ebola which were undergoing trials in the Democratic Republic of Congo have been stopped early due to their success in treating Ebola. The two treatments will now be made widely available. One of the drugs is REGN-EB3, a cocktail of three monoclonal antibodies developed by Regeneron Pharmaceuticals. The other drug is mAb114, which is now being developed with Ridgeback Biotherapeutics.
Researchers in Uganda have begun a two-year trial to assess the safety and immune response generated by a new two-dose Ebola vaccine manufactured by Janssen Vaccine and Prevention.
A fourth case of Ebola has been detected in the city of Goma. Healthcare workers in the city are working quickly to contain the spread of the virus throughout Goma.